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Moenomycin A (MmA) is a member of the phos-
phoglycolipid family of antibiotics, which are
the only natural products known to directly
target the extracellular peptidoglycan glycosyl-
transferases involved in bacterial cell wall bio-
synthesis. The structural and biological unique-
ness of MmAmake it an attractive starting point
for the development of new antibacterial drugs.
In order both to elucidate the biosynthesis of
this unusual compound and to develop tools
to manipulate its structure, we have identified
the MmA biosynthetic genes in Streptomyces
ghanaensis (ATCC14672). We show via heterol-
ogous expression of a subset ofmoe genes that
the economy of the MmA pathway is enabled
through the use of sugar-nucleotide and isopre-
noid building blocks derived from primary me-
tabolism. Thework reported lays the foundation
for genetic engineering of MmA biosynthesis to
produce novel derivatives.
INTRODUCTION
The emergence of resistance to existing antibiotics repre-
sents a significant threat to public health. The increasing
frequency of resistance to the cell wall inhibitor vancomy-
cin is of particular concern because this antibiotic is the
last line of defense against methicillin-resistant Gram-
positive infections. New antibiotics with activity against
resistant bacterial strains are desperately needed. Anti-
biotics that inhibit validated bacterial targets but are
structurally and mechanistically unrelated to compounds
in clinical use may be especially attractive candidates
for further development. One example of such a com-
pound is moenomycin A (MmA) (Figure 1), a phosphogly-
colipid antibiotic that is several orders of magnitude more
potent than vancomycin against many Gram-positive
pathogens, including the vancomycin-resistant patho-
gens [1]. MmA is a representative member of a family of
compounds that inhibit the peptidoglycan glycosyltrans-
ferases (also known as transglycosylases) involved in
bacterial cell wall formation [2]. Vancomycin also inhibitsChemistry & Biology 14, 25these enzymes, but the mechanisms of vancomycin and
MmA are completely unrelated. Whereas vancomycin
binds to peptidoglycan intermediates, which are sub-
strates for the peptidoglycan glycosyltransferases [3],
MmA binds to the peptidoglycan glycosyltransferases
themselves. The moenomycins are the only natural prod-
ucts known to have such a mechanism of action.
Paralleling the unusual mechanism of action of the
moenomycins is an unusual structure that contains an un-
precedented phosphoglycerate-ether linkage to an irregu-
lar isoprenoid chain. This structural feature, which is of con-
siderable interest from a biosynthetic standpoint, is also
believed to be the primary cause of the moenomycins’
poor physicochemical properties, which have hampered
their development as therapeutic agents for human use.
In the hope of learning how the phospholipid of MmA is as-
sembled and attached, and of acquiring tools to enable
the production of MmA analogs with better properties,
we sought to identify the genes for MmA production.
Access to these genes could enable the preparation of a
range of MmA derivatives to probe the mechanism of
peptidoglycan glycosyltransferase inhibition and the
structural requirements for activity, work that may lead
eventually to the discovery of peptidoglycan glycosyl-
transferase inhibitors for therapeutic use. Here, we report
the identification of the MmA biosynthetic genes from
Streptomyces ghanaensis (ATCC14672) by using a whole-
genome scanning approach combined with gene knock-
outs and complementation experiments. Analysis of the
gene cluster suggests that the MmA biosynthetic pathway
differs from previously characterized carbohydrate-con-
taining antibiotic gene clusters in that the sugar-nucleotide
buildingblocks, aswell asmost of the other buildingblocks
of the molecule, are derived exclusively from primary me-
tabolism. We have confirmed this hypothesis by demon-
strating that heterologous expression of a subset of the
MmA biosynthetic genes in S. lividans TK24 leads to the
production of a moenomycin pentasaccharide derivative.
Thus, the MmA cluster provides an alternative paradigm
for the biosynthesis of glycosylated secondary metabo-
lites that may influence genome-scanning approaches to
identify other carbohydrate-rich natural products. The
availability of a heterologous expression system for
moenomycinproductionwill facilitate analysis of gene func-
tion, and it may yield intermediates that can be chemically
modified to produce novel antibiotics or small-molecule
probes for bacterial peptidoglycan glycosyltransferases.7–267, March 2007 ª2007 Elsevier Ltd All rights reserved 257
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Moenomycin BiosynthesisFigure 1. Structures of MmA and
Proposed Structures of Moenomycins
Produced by Recombinant S. ghanaen-
sis and S. lividans Strains Described in
This Work
Capital letters A–H indicate the eight ‘‘building
blocks’’ of MmA.RESULTS
Identification of the Genes for C5N Subunit
Biosynthesis
Many gene clusters for antibiotic production have been
readily identified by degenerate primer-based PCR am-
plification of highly conserved genes [4]. Although struc-
turally unique, MmA does contain some features found
in other secondary metabolites. The most recognizable
one is perhaps the C5N subunit (A ring) (Figure 1). The bio-
synthesis of this subunit involves an aminolevulinate syn-
thase (ALS) [5], and we were able to amplify an internal
fragment of a putative ALS gene,moeC4, from the S. gha-
naensis genome by using degenerate primers based on
sequences of ALS genes proposed to govern the produc-
tion of asukamycin and the polyene ECO-02301 [5, 6]. Us-
ing this amplicon as a probe for screening a S. ghanaensis
SuperCos1-based gene library, we retrieved a cosmid,
moeno5, carrying the three-gene operon moeA4 moeB4
moeC4 (referred to here asmoe cluster 2) (Figure 2). Anal-
ysis of an S. ghanaensis moeA4-deficient strain, LH1, pre-
pared as described in Experimental Procedures, showed
that it did not produce MmA. Instead, it accumulated an
intermediate lacking the C5N chromophore that is pro-
posed to have the structure 2 (Figures 1 and 3B). Although
interruption of unit A attachment to the pentasaccharide
was expected to exclusively yield the galactopyranuronic
acid form of MmA (which was observed in the mutant as
a minor intermediate; data not shown), the exact mass
of themajor product supports the proposed structure (cal-
culated mass of the negative ion: 1484.6329, found:258 Chemistry & Biology 14, 257–267, March 2007 ª2007 Else1484.6371; MS2 spectra provided in Supplemental Data
available with this article online).
Compound 2 showed antibiotic activity, consistent with
experiments suggesting that the C5N subunit is not critical
for biological activity [7]. The introduction of plasmid
pKC11395-8 (which carries themoeC4-moeB4 intergenic
region and the entire moeB4 moeA4 genes) into the LH1
strain restored MmA biosynthesis, as evident from
LC-MS analysis. Expression of the moeB4 gene alone
(plasmid pOOB12) in the LH1 strain did not lead to MmA
production, implying that only moeA4 is affected in the
mutant. Based on sequence analysis, MoeA4 is proposed
tobeanacyl-CoA ligase that cyclizesaminolevulinate,while
MoeB4 is proposed to be an amide synthetase that cou-
ples the C5N unit to the C6 acid of the MmA B ring sugar
(Figure 4). Accumulation of the galactopyranouronamide
derivative 2 in MmA producers has been reported by other
laboratories [8] and may be due to amidation of unit B by
the same enzyme(s) that operates on unit F (Figure 1). Al-
though the preceding results establish a role for moeA4
moeB4 moeC4 genes in MmA production, none of the
genes flanking these three genes proved to be involved
in MmA production. We concluded that the primary moe
cluster must be elsewhere in the chromosome.
Identification of the Primary MmA Biosynthetic Gene
Cluster, moe Cluster 1
We attempted to clone the main MmA gene cluster by tar-
geting genes proposed to be involved in the biosynthesis
of the isoprenoid chain and some of the sugar subunits.
The isoprenoid chain in moenomycin was shown, by usingvier Ltd All rights reserved
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Moenomycin BiosynthesisFigure 2. Genetic Organization of MmA Biosynthetic Gene Clusters 1 and 2
The moe genes are located within cosmids moeno5, 38, and 40. B, BamHI restriction sites.tracer experiments, to be of nonmevalonate origin [9–11].
Nonmevalonate (also called DOXP)-pathway enzymes are
involved in the biosynthesis of all primary as well as some
secondary isoprene-derived metabolites in streptomy-
cetes. In one case, genes encoding DOXP-pathway en-
zymes have been found to be clustered with a natural
product pathway [12]. Efforts to identify the primary moe
cluster by targeting DOXP-pathway enzymes were unsuc-
cessful, however. Furthermore, all other attempts to clone
moe genes via a degenerate primer-based PCR approach
also failed: although a number of putative hexose 4,6-
dehydratase, carbamoyltransferase, and prenyltransferase
genes were cloned, none of them proved to be involved in
MmA production.
We considered several other strategies to identify the
primary moe cluster, including in vivo approaches (trans-
poson mutagenesis followed by screening for altered
MmA production/sensitivity; complementation of MmA
nonproducing mutants) and in silico whole-genome scan-
ning. After some experimental work aimed at testing vari-
ous in vivo approaches, we concluded that genome scan-
ning would be the most direct and reliable way to identify
the moe gene cluster. Advances in sequencing and soft-
ware technologies have reduced both the cost and the
time of the process to the point where whole-genome se-
quencing is competitive with other approaches as a tool
for the discovery of novel metabolic pathways.
The genome of S. ghanaensis ATCC14672 (8.6–9.0
Mb) was shotgun sequenced to 6.63 coverage and wasChemistry & Biology 14, 25partially assembled at the Broad Institute (Cambridge,
MA); this process yielded 1018 contigs ranging from 1 to
95 kb in size. The contigs cover 7.4Mb of the strain’s chro-
mosome. They were analyzed for the presence of candi-
date moe genes by using the BLASTX and FRAMEPLOT
[13] online programs. Contig 908 contained the previously
identified moe cluster 2. Four other neighboring contigs
(70–73), located more than 1 Mb away from contig 908
in the assembled genome, contained groups of genes
that appeared functionally capable of governing the bio-
synthesis of MmA. Two cosmids (moeno38 andmoeno40)
covering contigs 70–73 were retrieved from an S. gha-
naensis genomic library and fully sequenced to identify
a cluster of 20 moe genes (moe cluster 1) (Figure 2). The
boundaries of cluster 1 are defined by regions of extensive
synteny to the terminal region of the S. coelicolor chromo-
some [14]. The predicted functions of all moe genes are
presented in Table 1.
We confirmed the involvement ofmoe cluster 1 in MmA
biosynthesis through disruptions of genes moeGT1 and
moeM5, which encode a putative glycosyltransferase
(Gtf) and a carbamoyltransferase, respectively. Cell ex-
tracts from the mutants were analyzed for both antibiotic
activity and the presence of MmA analogs. The moeGT1-
deficient S. ghanaensis strain OB21e showed no anti-
biotic activity, and no peaks for MmA or its anticipated in-
termediates could be detected upon mass analysis of
OB21e semipurified extracts (Figure 3C) or culture broths.
Complementation of the OB21e mutant with plasmid7–267, March 2007 ª2007 Elsevier Ltd All rights reserved 259
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Moenomycin BiosynthesispOOB41, which carries a PermE-moeGT1 fusion, restored
MmA production, as judged from bioassays and LC-MS
analysis. The MmA trisaccharide degradation product
(units C, E, F, G, and H, Figure 1) is reported to have sub-
stantial antibacterial activity [15], suggesting that the
moeGT1 knockout blocks transfer of the C, E, or F rings.
The moeM5 null strain, OB20a, produced a compound
with greatly reduced antibiotic activity and a mass of
1537.6 Da ([M-H]) (Figure 3D), consistent with the loss
of the NH2CO group from the C
0-3 position of ring F of
MmA (Figure 1). Complementation of OB20a with
pOOB43, which carries a PermE-moeM5 fusion, restored
production of MmA, as judged by the reappearance of
a mass peak at 1580.6 Da. We suggest that MoeM5
acts as a late-stage tailoring enzyme to install the carba-
moyl group, which is an important element in the MmA
pharmacophore [1].
Description of moe Cluster 1
Cluster 1 contains genes encoding twoprenyltransferases,
five Gtfs, a 4,6-dehydratase/ketoreductase pair putatively
involved in C ring biosynthesis, a possible epimerase,
and several sugar-tailoring genes (Figure 2 and Table 1)
that are presumed to be involved in functionalization of
the F ring after pentasaccharide assembly. It also contains
Figure 3. HPLC-MS Analysis of Moenomycin Production by
Wild-Type and Recombinant S. ghanaensis Strains
(A–D) HPLC-MS analysis (ESI, negative mode) showing the moenomy-
cins found in cell extracts of S. ghanaensis (A) wild-type, (B) moeA4
mutant LH1, (C) moeGT1 mutant OB21e, and (D) moeM5 mutant
OB20a.260 Chemistry & Biology 14, 257–267, March 2007 ª2007 ElsevasecondALSgeneandagene forALAcyclization that con-
tains an in-frame deletion and is presumed to be nonfunc-
tional; however, there is no gene for attachment of the cy-
clized C5N unit. The biosynthetic moe cluster 2 most
likely arose fromduplicationof a chromophorebiosynthetic
operon frommoecluster1,whereupon the redundant chro-
mophoreoperon in cluster 1 subsequently underwent dele-
tionevents. In addition to theMmAbiosynthetic genes, four
genes encoding components of two ATP-binding cassette
(ABC) transport systems have been identified inmoe clus-
ter 1. ABC-type transporters are found in many antibiotic
gene clusters and are typically thought to be involved in
the transport of natural products or precursors across bac-
terial cell membranes [16]. Full descriptions of the moe
genes are provided in Supplemental Data.
The structures of the individual sugars in MmA and the
paucity of sugar biosynthetic genes in the cluster led us
to surmise that all of the NDP sugars in MmA must be de-
rived from building blocks produced by primary metabo-
lism. For example, the D ring donor is predicted to be
UDP-glucose; the E and C rings are predicted to share
a common precursor, UDP-GlcNAc, which is usedwithout
furthermodification as the E ring donor and is converted to
UDP-chinovosamine byMoeR5 andMoeS5 tomake the C
ring donor (Figure 4). The B and F rings in MmA are both
derived from C6 acid precursors, epimeric with respect
to the C4 hydroxyls. The B and F rings are predicted to
share a common precursor, however, because S. gha-
naensis also produces a moenomycin variant in which
the methyl substituent on the F ring is lacking [2], and in
this compound the C4 hydroxyl has the same stereo-
chemistry as the B ring. The common precursor is specu-
lated to be either UDP-glucuronic acid or UDP-galactur-
onic acid, both of which are used in exopolysaccharide
biosynthesis in streptomycetes. Uncertainty in the precise
nature of the donor arises becausemoe cluster 1 contains
a putative epimerase, MoeE5, that could modify UDP-
glucuronic acid to UDP-galacturonic acid. Other sugar-
tailoring genes include moeM5 for the carbamoyltrans-
ferase described above, as well as moeF5/moeH5 and
moeK5, which encode the putative amidotransferase sub-
units and a putative methylcobalamin-dependent radical
SAM methyltransferase [17, 18], respectively, that modify
the F ring (Figure 4).
The hypothesis that the sugars in MmA are derived from
primary metabolism is supported by sequence analysis of
the moe Gtfs themselves. The vast majority of Gtfs in-
volved in secondary metabolite biosynthesis are pre-
dicted to have a characteristic two-domain fold, known
as the GT-B superfamily fold [19]. These enzymes share
an easily recognizable sequence motif. Only one of the
Gtfs in moe cluster 1 is predicted to resemble Gtfs typi-
cally found in antibiotic production. This Gtf, MoeGT1,
shows strongest homology toMurG, an UDP-N-acetylglu-
cosaminyl transferase involved in transferring GlcNAc to
a glycolipid during peptidoglycan biosynthesis [20, 21].
Therefore, we suggest that MoeGT1 carries out a similar
reaction during MmA biosynthesis, namely, the transfer
of N-acetylglucosamine to a lipid-linked F ring precursorier Ltd All rights reserved
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Moenomycin BiosynthesisFigure 4. Proposed Biosynthetic Scheme for the Chromophore and Pentasaccharide Portions of MmA
Letters G–H in the shaded rectangle mark the lipid-phosphoglycerate moiety of MmA. MoeGTn represents any of four Moe Gtfs (MoeGT2–5).
UDP-GlcNAc, UDP-N-acetyl glucosamine; UDP-Glc, UDP-glucose; UDP-GlcA/UDP-GalA, UDP-glucuronic acid/UDP-galacturonic acid.(Figure 4). The other Gtfs show homology to Gtfs pro-
posed to be involved in exopolysaccharide biosynthesis
in various organisms. Thus, the Gtfs in moe cluster 1 are
more similar to enzymes known or thought to be involved
in primary metabolic processes than to enzymes typically
involved in natural product biosynthesis.
The use of building blocks from primary metabolism
apparently extends to the biosynthesis of the lipid-
phosphoglycerate chain of MmA. There are only two puta-
tive prenyltransferases in moe cluster 1, one of which,
MoeN5, shows homology to other prenyltransferases in-
volved in isoprenoid biosynthesis and is thus predicted
to be involved in the synthesis of the C25 lipid chain.
Schuricht et al. have proposed a mechanism for the for-
mation of the irregular isoprenoid chain of MmA that in-
volves the coupling of C15 and C10 subunits, both of which
could be derived from precursors produced in primary
metabolic pathways [1, 9–11]. Thus, a relatively complex
isoprenoid structure is apparently governed by a single
gene operating on available cellular metabolites (Figure 5).
The second prenyltransferase, MoeO5, is predicted to
catalyze formation of the ether linkage between 3-R-Chemistry & Biology 14, 2phosphoglycerate, an abundantmetabolite produceddur-
ing glycolysis, and the isoprenoid chain (Figure 5). MoeO5
shows sequence homology to the archaeal enzymes that
form the first ether linkage between isoprenoid precursors
and glycerol phosphate in the biosynthesis of the unusual
membrane lipids that distinguish Archaea from the other
kingdoms of life [22]. These archaeal prenyltransferases
have a TIM barrel fold, one of the most common folds in
nature, but unknown in other prenyltransferases [23].
MoeO5 is also predicted to have a TIM barrel fold, making
it the first, to our knowledge, bacterial homolog of the
archaeal prenyltransferases to be putatively assigned
a function. We note that MoeO5 homologs exist in a range
of bacteria and may catalyze similar prenyltransfer reac-
tions, which would suggest that bacteria produce other
metabolites that resemble archaeal membrane lipids.
Indeed, there is recent evidence that this is the case [24].
Heterologous Expression of a Subset ofmoe Cluster
1 in Streptomyces lividans TK24
We have proposed that moe cluster 1 encodes all of the
genes required to assemble a bioactive MmA derivative57–267, March 2007 ª2007 Elsevier Ltd All rights reserved 261
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Moenomycin BiosynthesisTable 1. Deduced Functions for Genes in Moenomycin A Gene Clusters 1 and 2
Protein AA Homolog ID%/SI%
Accession
Number Proposed Function
MoeA4 516 Putative acyl CoA ligase
(Streptomyces aizunensis)
63/73 AAX98210.1 Acyl CoA ligase
MoeB4 521 SimL (Streptomyces antibioticus) 45/62 AAG34163.1 Amide synthetase
MoeC4 412 HemA-AsuA (Streptomyces asukaensis) 70/83 AY240962 Aminolevulinate synthase
MoeB5 301 Putative acyl CoA ligase (S. aizunensis) 58/76 AAX98210.1 Nonfunctional acyl CoA ligasea
MoeA5 394 HemA-AsuA (S. asukaensis) 64/78 AY240962 Aminolevulinate synthase
MoeD5 591 Putative ABC transporter
(Symbiobacterium thermophilum)
41/55 YP075256.1 ABC transporter
MoeJ5 564 Same as above 45/61 YP075255.1 ABC transporter
MoeE5 340 Putative UDP-glucose 4-epimerase
(Symbiobacterium thermophilum)
46/58 YP074610.1 NDP-hexose 4-epimerase
MoeF5 645 WbpS (Pseudomonas aeruginosa) 29/43 AAF24002.1 Aminotransferase subunit 1
MoeGT1 402 Putative Gtf (Polaromonas sp) 27/40 EAM38951.1 Glycosyltransferase
MoeH5 513 AsnB-like amidotransferase
(Azoarcus sp)
32/48 CAI08539.1 Aminotransferase subunit 2
MoeK5 407 Putative methyltransferase
(Pyrococcus horikoshii)
34/52 NP_142754.1 Methyltransferase
MoeGT4 427 Putative Gtf (Mycobacterium vahbaalenii) 27/38 EAS23724.1 Glycosyltransferase
MoeM5 530 GdmN (Streptomyces hygroscopicus) 29/44 AAO06921.1 Carbamoyltransferase
MoeN5 260 Putative prenyltransferase
(Loktanella vestfoldensis)
29/43 EAQ07619.1 Prenyltransferase
MoeO5 281 GGGPS (Thermoplasma acidophilum) 27/43 JC7965 Prenyl 3-phosphoglycerate synthase
MoeX5 226 Putative membrane protein
(Mycobacterium sp)
26/40 EAS99725.1 ABC transporter membrane protein
MoeP5 223 ABC transporter ATPase
(Mycobacterium flavescens)
43/58 EAS11435.1 ABC transporter ATP-binding protein
MoeGT5 312 Gtf MoeGT4 (S. ghanaensis; see above) 45/59 Glycosyltransferase
MoeGT2 286 Putative Gtf (Methylococcus capsulatus) 35/51 AAU93096.1 Glycosyltransferase
MoeGT3 414 Putative Gtf (Kineococcus radiotolerans) 44/56 ZP_00616987.1 Glycosyltransferase
MoeR5 374 CapD (Nocardioides sp) 53/68 EAO07657.1 Hexose-4,6-dehydratase
MoeS5 282 SCO7194 (Streptomyces coelicolor) 62/75 CAC01594.1 Hexose-4-ketoreductase
AA, amino acids. For references citing moe gene homologs, see Supplemental Data.
a See Supplemental Data.lacking the chromophore unit (compound 2, Figure 1) from
cellular pools of available metabolites. To test this hypoth-
esis, we constructed cosmid moeno38-1 from cosmid
moeno38, in which the neo gene marker has been re-
placed with the 5.3 kb hyg-oriTRK2-intfC31 PCR fragment
of vector pOOB40 by using the l-RED recombination ap-
proach [25, 26]. In a similar manner, the neo gene was re-
placed in the SuperCos1 vector to produce SuperCos1Hy.
Cosmid moeno38-1 contains all of the moe cluster 1
genes exceptmoeR5moeS5, which are proposed to con-
vert UDP-GlcNAc to UDP-chinovosamine. This cosmid
was transferred conjugally into S. lividans TK24, and the
presence of moeno38-1 in the TK24 strain was confirmed262 Chemistry & Biology 14, 257–267, March 2007 ª2007 Elseviby PCR with primers specific to moeGT1, moeGT3, and
attRfC31 [27]. Biochromatography showed that the cell ex-
tract and culture broth from the moeno38-1+ TK24 trans-
conjugant, but not from a strain harboring the empty vec-
tor SuperCos1Hy, contain a biologically active compound
(Figure 6). HPLC analysis showed that the compound has
the samemobility andUV spectrum as theMmAprecursor
2 lacking the C5N chromophore unit. High-resolution MS
analysis showed that the new compound has a mass of
1500.6278 Da ([M-H]). MS/MS analysis of the compound
revealed several characteristic mass peaks commonly
observed during fragmentation of moenomycins (Supple-
mental Data). Based on HPLC mobility, exact mass,er Ltd All rights reserved
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Moenomycin Biosynthesisand biological data, the compound is proposed to be a
pholipomycin derivative lacking the chromophore unit
(compound 4, Figure 1; calculated mass of the negative
ion: 1500.6278 Da). Pholipomycin is a known member of
the moenomycin family in which the C ring is N-acetylglu-
cosamine rather than chinovosamine [2]. Exclusive pro-
duction of a pholipomycin precursor by the recombinant
S. lividans strain is consistent with the proposed roles of
the moeR5 moeS5 genes in the biosynthesis of UDP-
chinovosamine from UDP-GlcNAc. These data also in-
dicate that the Gtf responsible for unit C attachment can
accept not only UDP-chinovosamine, but also UDP-
GlcNAc. This finding is consistent with recent studies
showing that the moenomycin complex of antibiotics pu-
rified from S. ghanaensis also contains pholipomycin (or
6C-hydroxy-MmA) as a component [8]. Most important,
the results show that cosmid moeno38-1 carries all of
the genes necessary for formation of the moenomycin
pentasaccharide phospholipid scaffold, confirming that
the building blocks of the molecule are supplied from
Figure 5. Proposed Scheme for the Biosynthesis of Lipid-
Phosphoglycerate Moiety 4 of MmA
The letters ‘‘PPO’’ in the shaded rectangle represent pyrophosphate.
1, farnesyl pyrophosphate; 2, C10 isoprenoid precursor. Intermediates
on the pathway to moenocinol pyrophosphate 3 were postulated
by Schuricht et al. [10]. 3-R-PG, 3-phosphoglycerate. The formation
of 1 with the cis configuration could be governed by a primary metab-
olism enzyme similar to M. tuberculosis Z-farnesyl diphosphate
synthase [43].Chemistry & Biology 14, 2cellular metabolite pools. Based on sequence analysis
and the results of heterologous moe gene expression, we
suggest that production of a fully active 1.4 kDa MmA
precursor will take only nine dedicated genes (12 kb
DNA fragment), six of which govern the assembly of the
phosphoglycolipid scaffold and three of which direct two
biologically important sugar-tailoring reactions (carba-
moylation and carboxyamidation of unit F).
DISCUSSION
To our knowledge, the cloning and analysis of the genes
governing MmA production provide the first insight into
the genetics of phosphoglycolipid antibiotic biosynthesis.
Certain features of the MmA biosynthetic pathway merit
further comment. First, the involvement of groups of
genes at two widely separated loci in natural product
biosynthesis is rare, but not completely unprecedented
[28, 29]. More unusual is the size of the primarymoe clus-
ter 1, which is remarkably small (<30 Kb) given the size of
the molecule produced (1583 Da). The antibiotic calichea-
micin, which has a mass similar to that of MmA (1364 Da)
and contains four sugar subunits, is produced by a gene
cluster that is more than three times larger and contains
many more ORFs than moe cluster 1 [30]. A comparison
of the clusters for the biosynthesis of MmA, calicheamicin,
and other antibiotics containing multiple sugar subunits
reveals a striking difference: the moe cluster contains
very few genes involved in the biosynthesis of the individ-
ual sugar subunits. With few exceptions [31, 32], gene
Figure 6. Biochromatography of Methanol Extracts
Biochromatography of S. lividans (lane A) TK24 moeno38-1+ cell ex-
tracts and (lane B) culture broth and S. lividans (lane C) TK24 Super-
Cos1Hy+ cell extracts and (lane D) culture broth. The MmA standard
(10 mcg) is in lane E.57–267, March 2007 ª2007 Elsevier Ltd All rights reserved 263
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Moenomycin Biosynthesisclusters for glycosylated metabolites contain nucleotidyl-
transferases. However, there is not a single nucleotidyl-
transferase gene in the moe cluster, and other sugar
biosynthetic genes are sparse as well.
We have demonstrated via heterologous expression of
a subset of genes from moe cluster 1 that all of the sugar
building blocks (as well as the building blocks of the
moenocinol-phosphoglycerate moiety) are derived from
primary metabolism and are used either directly or with
minimal modification to produce the pentasaccharide
scaffold of MmA, which is subsequently tailored on the
B and F rings. Althoughmany other types of antibiotics de-
rive building blocks from cellular metabolite pools, carbo-
hydrate-containing antibiotic gene clusters typically con-
tain a great many genes devoted to sugar biosynthesis.
In fact, it was recently suggested that the formation of
NDP sugar precursors by dedicated nucleotidyltrans-
ferases represents a crucial branching point of secondary
carbohydrate metabolic pathways from primary metabo-
lism [33]. The discovery ofmoe cluster 1 shows that there
is another paradigm for the synthesis of carbohydrate-rich
secondary metabolites.
MmA is produced late in the streptomycetes’ life cycle
[34], consistent with its role as a secondary metabolite,
but the building blocks used to assemble the molecule
are expected to be present throughout cell growth. Appar-
ently, they are used to construct MmA only when themoe
genes are transcribed. The regulation ofmoe cluster gene
expression is unclear because it appears to lack dedi-
cated regulatory genes. However, the moeA5, moeO5,
moeR5, and moeE5 genes all contain rare TTA leucine
codons. In S. coelicolor, 50-processed LeutRNA
UUA is ac-
cumulated in significant quantities only in late stationary
phase [35], thus setting an important regulatory switch
for antibiotic production [36]. Fewer than 0.2% of genes
in the S. coelicolor genome contain TTA codons [36].
Therefore, the appearance of this codon in 20% of the
genes within moe cluster 1 seems significant and sug-
gests that, in S. ghanaensis, MmA production is coinci-
dent with the increased accumulation of the mature
tRNA for TTA codon expression late in growth.
It is worth asking whether the MmA biosynthetic
pathway, with its heavy reliance on available primary me-
tabolite pools, represents a special case or a common
paradigm for the synthesis of glycosylated secondary me-
tabolites. We favor the latter possibility, and we suggest
that an appropriate search of bacterial genomes will turn
up previously unrecognized natural product gene clusters
having a genetic architecture similar to that members of
moe cluster 1. For example, the genome of the enterobac-
terium Photorhabdus luminescens contains a cluster of
genes (plu3353–plu3368) encoding five putative Gtfs
(one shows homology to both MoeGT4 and MoeGT5), one
MoeO5 homolog, a prenyltransferase, as well as a set of
hypothetical proteins [37]. The genetic capacity of this
cluster is enough to direct the formation of a phosphogly-
colipid molecule. This and other clusters may have been
overlooked as potential determinants of antibiotics or other
bioactive compounds both because of their economy264 Chemistry & Biology 14, 257–267, March 2007 ª2007 Elseand because many of the carbohydrate-processing
genes, like those in the MmA cluster, bear a stronger
resemblance to genes involved in primary metabolism
than to those involved in secondarymetabolism. Thus, be-
sides providing us with genetic tools for manipulating
MmA structure, the discovery of theMmA cluster provides
new, to our knowledge, insights into the biosynthesis of
carbohydrate-containing natural products that may be
useful in the annotation of bacterial genomes.
SIGNIFICANCE
MmA is a chemically and biologically unique phos-
phoglycolipid antibiotic with potent activity against
Gram-positive bacteria, including vancomycin- and
methicillin-resistant pathogens. Development of novel
antibacterial drugsbasedon theMmApharmacophore
is hampered by our poor understanding of the mecha-
nisms of MmA inhibition as well as limited chemical
tools for manipulating MmA structure. The cloning of
the MmA biosynthetic genes paves the way for the
combinatorial biosynthesis and chemoenzymatic
synthesis ofmoenomycin derivatives for use as antibi-
otics and as chemical probes to understand better the
mechanismof action of bacterial peptidoglycan glyco-
syltransferases involved in peptidoglycan biosynthe-
sis and remodeling. The genetic organization of MmA
pathway itself is remarkable for the apparent absence
of genes for the formation of activated sugars, isopre-
noid metabolism, and regulation, as well as for the
presence of such novel genes asmoeO5, which is ho-
mologous to prenyltransferases involved in archaeal
membrane biosynthesis. Thus, impressive streamlin-
ing of the moe cluster and the presence of genes for
unusual biotransformations are two salient features
of the MmA biosynthetic pathway. To our knowledge,
the MmA biosynthetic pathway provides new insights
into secondary metabolism that may lead to the dis-
covery of previously unrecognized natural product
clusters in other bacterial genomes.
EXPERIMENTAL PROCEDURES
Antibiotics
Pure MmA was provided by M. Adachi and S. Fuse (Department of
Chemistry andChemical Biology, HarvardUniversity). For recombinant
strain selection, commercially available antibioticswere used (mcg/ml):
ampicillin (100), chloramphenicol (35), kanamycin (50), apramycin (50),
hygromycin (100), spectinomycin (200), and streptomycin (100).
Strains and Vector DNAs
Streptomyces ghanaensis ATCC14672 and Bacillus cereus
ATCC19637 were obtained from ATCC. S. lividans TK24 was kindly
provided by M. Kobayashi (University of Tsukuba, Japan). E. coli XL1
Blue MR and cosmid SuperCos1 were purchased from Stratagene.
The methylation-deficient conjugative strain E. coli ET12567
(pUB307) [38] was obtained from Prof. C.P. Smith (Manchester Univer-
sity, UK). E. coli BW25113 (pIJ790) was obtained from the John Innes
Center (Norwich, UK). S. ghanaensis strains LH1, OB20a, and OB21e
with disrupted moeA4, moeM5, and moeGT1 genes, respectively,
were constructed as described in this work. The vector pKC1139vier Ltd All rights reserved
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pSET152 [39] were obtained from Prof. C.P. Smith. Vector pMKI9
was constructed by the cloning of a 0.2 kb HindIII-XbaI fragment
carrying the ermE promoter into respective sites of the pKC1139 poly-
linker (provided by I. Ostash, L’viv University, Ukraine). To generate
vector pOOB40, the central portion of the apramycin-resistance gene
aac(3)IV in vector pSET152 had been excised with SacI endonuclease,
and the rest of the vector had been treated with Klenow fragment and
ligated to the EcoRV-digested hygromycin-resistance cassette hyg
[39]. Vector pOOB5, which carries the spectinomycin-resistance
marker aadA instead of aac(3)IV, was generated in the same way.
DNA Manipulations and Analysis
Standard molecular biology procedures were used throughout this
work [39, 40]. The plasmid and fosmid libraries for S. ghanaensis
ATCC14672 genome sequencing were created at the Broad Institute.
Sequencing of cosmids moeno5, 38, 40 and their subclones was done
at the Biopolymers Facility of Harvard Medical School by using stan-
dard (M13, T7, T3) and custom-designed primers. The generation,
assembly, and analysis of S. ghanaensis genomic sequences will be
described separately. BLAST search tools (on the server of the
National Center for Biotechnology Information, Bethesda,MD), Frame-
Plot2.3.2 [13], CUPplot1.0 (at www.nih.go.jp/-jun/cgi-bin/frameplot.pl),
and the Lasergene software package were used for S. ghanaensis
sequence assembly, analysis, and annotation. The CDD search engine
(BLAST server) and a set of programs (HHPred, Pfam, TMHHM) on the
ExPaSy proteomics server were utilized for identification of topology
and conserved domains of Moe proteins.
The S. ghanaensis genomic library has been constructed by
using SuperCos1. DIG-labeled internal fragments of genes moeC4,
moeGT1, and moeGT3 amplified from the chromosome (primers are
described in Supplemental Data) were used as hybridization probes
for library screening. The 5.3 kb fragment of pOOB40 (hyg-oriT-int cas-
sette) was engineered into cosmid moeno38 by utilizing the primers
and the strategy reported by Yanai et al. [41].
Generation of S. ghanaensis Disruption Mutants
and Their Analysis
S. ghanaensis transconjugants (obtained according to described
procedures; [39]) carrying pKC1139-based disruption plasmids in rep-
licative form were grown for 3 days in tryptic soy broth (TSB; Difco) at
30C. The biomasswas washed twice with water to remove apramycin
used for plasmid selection, and105 cfuwere inoculated into freshTSB
without antibiotic. The culture was incubated for 6 days at 40C (to
eliminate free plasmid), plated onto LB agar supplemented with apra-
mycin, and grown for 4–5 days at 37C. Colonies with disruption plas-
mids integrated into thegene of interestwere obtainedwith a frequency
of 33105 to 43105.Noapramycin-resistant coloniesweredetected
in a control strain carrying the empty vector, implying that the frequency
of nonspecific integration of pKC1139 is below the level of detection
(we usually plated 33 108 cfu), and that the appearance of AmR colo-
nies in the experimental strains is due tohomologous integration.More-
over, ten independent coloniesof eachdisruptionmutantwere assayed
for MmA production, and in no case could we detect theMmA+ pheno-
type due to possible nonspecific integration of the plasmid into the S.
ghanaensis genome. We also did not detect reversions to the AmS
and MmA+ phenotypes when the strains were grown in the presence
of apramycin at 37C, indicating that, under the stated conditions,
the pKC1139-based plasmids are stably integrated into the homology
region of generatedmutants (3000–4000 colonies have been assayed).
Passage of wild-type strains under the cultivation conditions used to
generatemoemutants did not affect MmA production. The knockouts
were verified by Southern analysis by using the internal fragments of
disrupted genes as probes. For complementation experiments, mat-
ings of S. ghanaensismutants with donor E. coli strains were incubated
at 37C and were overlaid after 8 hr of growth. Control conjugations
with empty vectors (either pOOB5 [Spr] or pOOB40 [Hyr]) were per-
formed, and the obtained transconjugants were analyzed in parallelChemistry & Biology 14, 2with experimental strains to ensure that workup conditions did not
affect the stability of MmA mutants.
Moenomycin Production Analysis
For all moenomycin extraction procedures, equal amounts of biomass
(2 g, wet weight) and fermentationmedium (30ml) were used. ForMmA
production, S. ghanaensis mutants with disrupted moe genes and
S. lividans strains were grown at 37C for 4–5 days in mTSB (TSB sup-
plemented with trace elements solution [39], 0.8 ml per 1 liter). For an-
tibiotic disc diffusion assays, fermentation medium and concentrated
methanol extracts of MmA from mycelium of streptomycete strains
were applied to antibiotic assay discs (10 mm, Sigma) and stacked
onto LA plates overlaid with soft agar containing MmA-sensitive
B. cereus. Zones of B. cereus growth inhibition were observed after
12–14 hr of incubation at 30C. Moenomycins were partially purified
(60%purity) from the cell extracts by using a 100mgC18 SPE cartridge
(Waters) and were analyzed by LC-MS as described in [42] on an
Agilent 1100 series LC/MSD machine. For biochromatography, moe-
nomycin extracts were separated on silica gel aluminum TLC plates
(mobile phase: methanol:acetonitrile:water at 35:40:25), which were
dried and overlaid with soft agar containing B. cereus. After overnight
incubation at 30C, the plates were visualized with visible and UV light
(254 nm). Accurate mass spectra of purified moenomycins from
recombinant S. ghanaensis LH1 and S. lividans TK24 (moeno38-1)
strains were acquired by using an Agilent LC/MSD TOF machine. For
the LC analysis, a Gemini C18 column (5 mm, 4.6 mm 3 100 mm)
from Phenomenex was used (mobile phase A: H2O and mobile phase
B: acetonitrile, with 0.1% ammonium hydroxide as a solvent modifier).
Samples were run in negative ionization mode; the capillary voltage
was set to 4.0 kV, and the fragmentor voltage was set to 150 V. The
drying gas temperature was 300C, the drying gas flow rate was
7 l/min, and the nebulizer pressure was 15 psi. ()ESI-MS2 spectra
of compounds 2 and 4 were acquired with a Micromass qTOF2
machine. Cone and capillary voltages were set to 35 V and 3 kV,
respectively; collision energy was 30 V.
Supplemental Data
Supplemental Data, including a detailed description of moe genes,
primer sequences, plasmid construction, mutant strain verification,
and MS/MS analysis are available at http://www.chembiol.com/cgi/
content/full/14/3/257/DC1/.
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